The U.S. Food and Drug Administration has requested additional information from Telix Pharmaceuticals regarding its experimental diagnostic tool for a form of kidney cancer. This development underscores the regulatory rigor that emerging medical products must meet before approval.

Analysts at Wedbush project that Telix Pharmaceuticals could achieve an earnings per share of $0.89 by 2028. The research note, released on August 21st, underscores the potential growth trajectory for the pharmaceutical company in the coming years.